Kineta Inc. was formed in December 2007 by a group of scientists who are globally recognized for several breakthrough discoveries about the human immune system and the body’s reaction to the Hepatitis C virus. Through Kineta, our pioneering team is dedicated to further study of innate immunity with an aggressive strategy to develop early stage programs for powerful new antiviral and immune modulating drugs. We believe our unique approach will yield a new class of drugs to respond to diseases caused by viruses such as, Influenza, Hepatitis C and West Nile virus: diseases that afflict millions of people. This novel field of research is also applicable to dozens of autoimmune diseases. We believe in our science and our ability to improve lives around the world.